These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9807841)

  • 21. Assessing adenoviral hammerhead ribozyme and small hairpin RNA cassettes in neurons: inhibition of endogenous caspase-3 activity and protection from apoptotic cell death.
    Bantounas I; Glover CP; Kelly S; Iseki S; Phylactou LA; Uney JB
    J Neurosci Res; 2005 Mar; 79(5):661-9. PubMed ID: 15657876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ribozymes as therapeutic tools for genetic disease.
    Phylactou LA; Kilpatrick MW; Wood MJ
    Hum Mol Genet; 1998; 7(10):1649-53. PubMed ID: 9735387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of hammerhead ribozymes to modulate endogenous gene expression for functional studies.
    Fritz JJ; Lewin A; Hauswirth W; Agarwal A; Grant M; Shaw L
    Methods; 2002 Oct; 28(2):276-85. PubMed ID: 12413427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel functional genomics approach identifies mTERT as a suppressor of fibroblast transformation.
    Li QX; Robbins JM; Welch PJ; Wong-Staal F; Barber JR
    Nucleic Acids Res; 2000 Jul; 28(13):2605-12. PubMed ID: 10871412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake.
    Bramlage B; Alefelder S; Marschall P; Eckstein F
    Nucleic Acids Res; 1999 Aug; 27(15):3159-67. PubMed ID: 10454613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
    Phylactou LA; Tsipouras P; Kilpatrick MW
    Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity.
    Yokoyama Y; Takahashi Y; Shinohara A; Wan X; Takahashi S; Niwa K; Tamaya T
    Biochem Biophys Res Commun; 2000 Jun; 273(1):316-21. PubMed ID: 10873604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding.
    Trang P; Hsu A; Zhou T; Lee J; Kilani AF; Nepomuceno E; Liu F
    J Mol Biol; 2002 Jan; 315(4):573-86. PubMed ID: 11812131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells.
    Choi KS; Lee TH; Jung MH
    Cancer Gene Ther; 2003 Feb; 10(2):87-95. PubMed ID: 12536196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective anti-hepatitis B virus hammerhead ribozymes derived from multimeric precursors.
    Weinberg MS; Ely A; Passman M; Mufamadi SM; Arbuthnot P
    Oligonucleotides; 2007; 17(1):104-12. PubMed ID: 17461767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, characterization and testing of tRNA3Lys-based hammerhead ribozymes.
    Medina MF; Joshi S
    Nucleic Acids Res; 1999 Apr; 27(7):1698-708. PubMed ID: 10076002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells.
    Passman M; Weinberg M; Kew M; Arbuthnot P
    Biochem Biophys Res Commun; 2000 Feb; 268(3):728-33. PubMed ID: 10679273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The virtues of self-binding: high sequence specificity for RNA cleavage by self-processed hammerhead ribozymes.
    Ohmichi T; Kool ET
    Nucleic Acids Res; 2000 Feb; 28(3):776-83. PubMed ID: 10637330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exogenous control of mammalian gene expression through modulation of RNA self-cleavage.
    Yen L; Svendsen J; Lee JS; Gray JT; Magnier M; Baba T; D'Amato RJ; Mulligan RC
    Nature; 2004 Sep; 431(7007):471-6. PubMed ID: 15386015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa.
    Drenser KA; Timmers AM; Hauswirth WW; Lewin AS
    Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):681-9. PubMed ID: 9538873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA.
    Cai DW; Mukhopadhyay T; Roth JA
    Cancer Gene Ther; 1995 Sep; 2(3):199-205. PubMed ID: 8528963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cleavage of viral RNA and inhibition of viral translation by hepatitis C virus RNA-specific hammerhead ribozyme in vitro.
    Ohkawa K; Yuki N; Kanazawa Y; Ueda K; Mita E; Sasaki Y; Kasahara A; Hayashi N
    J Hepatol; 1997 Jul; 27(1):78-84. PubMed ID: 9252077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral activity of RNA molecules containing self-releasing ribozymes targeted to lymphocytic choriomeningitis virus.
    Xing Z; Mahadeviah S; Whitton JL
    Antisense Res Dev; 1995; 5(3):203-12. PubMed ID: 8785476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The structure, function and application of the hammerhead ribozyme.
    Birikh KR; Heaton PA; Eckstein F
    Eur J Biochem; 1997 Apr; 245(1):1-16. PubMed ID: 9128718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.